NORTH Dakota | Health & Human Services
Be Legendary.

HEALTH ALERT NETWORK | HEALTH ADVISORY | November 30, 2022

Bebtelovimab is no longer authorized for use

The U.S. Food and Drug Administration (USFDA) announced Wednesday, Nov. 30, Bebtelovimab is no longer authorized for emergency use in the U.S. The USFDA came to this decision because Bebtelovimab is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1., according to data included in the Health Care Provider Fact Sheet.

The combined proportion of COVID-19 cases caused by the Omicron BQ.1 and BQ.1.1 subvariants are above 57% in all U.S. regions except one. Data shows that this trend of increasing prevalence will be sustained. Given that a COVID-19 infection is likely to be caused by a non-susceptible SARS-CoV-2 variant and is consistent with the terms and conditions of the Letter of Authorization, Bebtelovimab is not currently authorized for emergency use in any U.S. region at this time.

Health care providers should remain aware that other COVID-19 treatments remain effective against the BQ.1 and the BQ.1.1 variants and should select the treatment appropriate for the patient. In addition, COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies is authorized for the treatment of COVID-19 in patients with immunosuppressive disease or receiving immunosuppressive treatment in either inpatient or outpatient settings.

Facilities are encouraged to keep any Bebtelovimab that they have on hand in the event that it is effective against any new strains or previous strains that become more prevalent in the future.

Attached is further information, and if you have any questions you can contact the ND Health and Human Services Operation center at 701-328-0707